Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurélie Mahalatchimy

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Medical Law Review|April 17, 2016
REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCEAurélie Mahalatchimy
Regenerative Medicine|October 4, 2017
The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politicsAurélie Mahalatchimy, Alex Faulkner
Journal International De Bioethique Et D'Ethique Des Sciences|February 16, 2019
[Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation]Aurélie Mahalatchimy, Nathalie De Grove-Valdeyron
European Journal of Health Law|May 7, 2026
Understanding European Union Substances of Human Origin Case Law through Defragmentation and FragmentationAurélie Mahalatchimy, Marie Glinel, Tamara K Hervey
Journal International De Bioethique Et D'Ethique Des Sciences|March 22, 2018
Emmanuelle Rial-Sebbag, Aurélie Mahalatchimy, Anne-Marie Duguet
Regenerative Medicine|November 7, 2015
Are there specific translational challenges in regenerative medicine? Lessons from other fieldsJohn Gardner, Alex Faulkner, Aurélie Mahalatchimy, et al.
Journal of Law and Society|April 26, 2012
The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United KingdomAurélie Mahalatchimy, Emmanuelle Rial-Sebbag, Virginie Tournay, et al.
Journal of Law and the Biosciences|August 19, 2021
Framing and legitimating EU legal regulation of human gene-editing technologies: key facets and functions of an imaginaryAurélie Mahalatchimy, Pin Lean Lau, Phoebe Li, et al.
Cytotherapy|July 9, 2025
Mapping the European landscape and specificity of ATMPs guidanceAurélie Mahalatchimy, Valentin Roby, Julie Véran, et al.
Nature Biotechnology|January 10, 2015
The impact of European embryonic stem cell patent decisions on research strategiesAurélie Mahalatchimy, Emmanuelle Rial-Sebbag, Anne-Marie Duguet, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Medical Law Review|April 17, 2016
REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCEAurélie Mahalatchimy
Regenerative Medicine|October 4, 2017
The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politicsAurélie Mahalatchimy, Alex Faulkner
Journal International De Bioethique Et D'Ethique Des Sciences|February 16, 2019
[Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation]Aurélie Mahalatchimy, Nathalie De Grove-Valdeyron
European Journal of Health Law|May 7, 2026
Understanding European Union Substances of Human Origin Case Law through Defragmentation and FragmentationAurélie Mahalatchimy, Marie Glinel, Tamara K Hervey
Journal International De Bioethique Et D'Ethique Des Sciences|March 22, 2018
Emmanuelle Rial-Sebbag, Aurélie Mahalatchimy, Anne-Marie Duguet
Regenerative Medicine|November 7, 2015
Are there specific translational challenges in regenerative medicine? Lessons from other fieldsJohn Gardner, Alex Faulkner, Aurélie Mahalatchimy, et al.
Journal of Law and Society|April 26, 2012
The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United KingdomAurélie Mahalatchimy, Emmanuelle Rial-Sebbag, Virginie Tournay, et al.
Journal of Law and the Biosciences|August 19, 2021
Framing and legitimating EU legal regulation of human gene-editing technologies: key facets and functions of an imaginaryAurélie Mahalatchimy, Pin Lean Lau, Phoebe Li, et al.
Cytotherapy|July 9, 2025
Mapping the European landscape and specificity of ATMPs guidanceAurélie Mahalatchimy, Valentin Roby, Julie Véran, et al.
Nature Biotechnology|January 10, 2015
The impact of European embryonic stem cell patent decisions on research strategiesAurélie Mahalatchimy, Emmanuelle Rial-Sebbag, Anne-Marie Duguet, et al.
Pageof 2